-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 10, 2021, Santen and Sydnexis announced that they have reached an exclusive license agreement for the development and promotion of Sydnexis's low-dose atropine preparation SYD-101 in Europe, the Middle East and Africa (EMEA)
.
SYD-101 solves the problem of the stability of low-concentration atropine in a neutral environment, and is used to treat myopia in children
As one of the most common eye diseases, myopia is a growing public health challenge that is expected to affect 5 billion people worldwide by 2050
.
The increase in morbidity and disease severity is mainly due to life>
As an inhibitor of M cholinergic receptors, atropine eye drops were originally used for mydriatic refraction
.
Scientists later discovered that low concentrations of atropine are effective in treating myopia
▲The molecular structure of atropine (photo source: Harbin, Public domain, via Wikimedia Commons)
SYD-101 is an under-development low-dose atropine sulfate eye drops, which aims to achieve the curative effect of treating myopia in children, while enhancing the pharmacological stability and reducing discomfort, so as to improve the continuity of treatment
.
SYD-101 does not need to lower the pH value, and can reach a validity period of up to 3 years at room temperature
“Children’s eye health is an important part of their overall health
.
As part of this agreement, we will work together to bring SYD-101 to the EMEA market,” said Mr.
Reference materials:
[1] Santen and Sydnexis execute an exclusive licensing agreement for SYD-101, a novel investigational treatment for progressive childhood myopia.